SGMO - Sangamo Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
11.07
-0.34 (-2.98%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close11.41
Open11.47
Bid9.10 x 1200
Ask13.00 x 1000
Day's Range10.69 - 11.60
52 Week Range9.00 - 27.50
Volume1,424,808
Avg. Volume1,768,479
Market Cap1.13B
Beta (3Y Monthly)3.48
PE Ratio (TTM)N/A
EPS (TTM)-0.68
Earnings DateFeb 20, 2019 - Feb 25, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.71
Trade prices are not sourced from all markets
  • PR Newswire2 days ago

    Sangamo Announces Treatment Of First Patient In Phase 1/2 Clinical Trial Of In Vivo Genome Editing Therapy For Hemophilia B

    Hemophilia B is a rare, genetic bleeding disorder caused by a lack of the factor IX (FIX) protein, which is necessary for normal blood clotting. SB-FIX uses Sangamo's proprietary zinc finger nuclease (ZFN) genome editing to insert into the DNA of liver cells a corrective copy of the F9 gene, which controls the production of FIX.

  • Zacks8 days ago

    Gilead Sciences (GILD) Appoints Daniel O'Day as New CEO

    Gilead Sciences (GILD) names Roche's Daniel O'Day as the company's new Chairman and CEO.

  • Gilead's (GILD) Harvoni and Descovy Get Approval in China
    Zacks14 days ago

    Gilead's (GILD) Harvoni and Descovy Get Approval in China

    Gilead's (GILD) HCV drug Harvoni and HIV cocktail therapy Descovy get approval in China.

  • Gilead (GILD) Announces Data on CAR T Therapy Candidate
    Zacks15 days ago

    Gilead (GILD) Announces Data on CAR T Therapy Candidate

    Gilead (GILD) announces data on chimeric antigen receptor T (CAR T) cell therapy candidate at the ASH for the treatment of patients with relapsed or refractory acute lymphoblastic leukemia.

  • Is Sangamo Therapeutics Inc (NASDAQ:SGMO) A Financially Sound Company?
    Simply Wall St.15 days ago

    Is Sangamo Therapeutics Inc (NASDAQ:SGMO) A Financially Sound Company?

    The direct benefit for Sangamo Therapeutics Inc (NASDAQ:SGMO), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off Read More...

  • PR Newswire16 days ago

    Sangamo Announces Completion Of TxCell Acquisition

    RICHMOND, Calif. and VALBONNE, France, Dec. 3, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO) today announced the completion of the acquisition of TxCell, SA. TxCell is now a subsidiary of Sangamo and has been delisted from the French stock market. "The acquisition of TxCell immediately positions Sangamo as the leader in CAR-Treg development," said Sandy Macrae, CEO of Sangamo. In 2019, Sangamo expects to submit a clinical trial authorization application (CTA) in Europe for TxCell's first CAR-Treg investigational product candidate for solid organ transplant.

  • Better Buy: Editas Medicine vs. Sangamo Therapeutics
    Motley Fool17 days ago

    Better Buy: Editas Medicine vs. Sangamo Therapeutics

    Gene editing comes in different flavors. Which of these gene-editing biotech stocks is tastier?

  • How Much Upside Wall Street Sees in Sangamo Stock
    Market Realist19 days ago

    How Much Upside Wall Street Sees in Sangamo Stock

    In November, of the total eight analysts covering Sangamo Therapeutics (SGMO), five have given the stock a “buy” or higher rating and three analysts have given it a “hold” rating. The mean rating for Sangamo Therapeutics stock is 2.0 with a target price of $22.71, implying an upside potential of 90.5% over the closing price of $11.92 on November 29.

  • Taking Stock of Sangamo’s Financial Performance
    Market Realist19 days ago

    Taking Stock of Sangamo’s Financial Performance

    Sangamo Therapeutics (SGMO) focuses on developing and bringing to market novel genomic therapies. Its genome editing and gene regulation technology platform is enabled by engineering transcription factors called zinc finger DNA-binding proteins, which can increase or decrease gene expression or gene regulation.

  • Analyzing Sangamo Therapeutics’ Operational Performance
    Market Realist19 days ago

    Analyzing Sangamo Therapeutics’ Operational Performance

    Sangamo Therapeutics (SGMO) incurred general and administrative expenses of $10.99 million in the third quarter of 2018, compared with $6.42 million in the third quarter of 2017. The fiscal 2018 research and development expenses for peers Amgen (AMGN), Biogen (BIIB), and Gilead Sciences (GILD) are expected at $3.52 billion, $2.48 billion, and $3.71 billion, respectively. Sangamo Therapeutics’ net interest and other income grew from $681,000 in the third quarter of 2017 to $3.4 million in the latest quarter.

  • GlobeNewswire21 days ago

    Report: Developing Opportunities within Costco Wholesale, Pepsico, Northern Oil and Gas, Codexis, Sangamo Therapeutics, and BRF S.A. — Future Expectations, Projections Moving into 2018

    NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Gilead's HIV Franchise, CAR T Therapy Likely to Propel Growth
    Zacks23 days ago

    Gilead's HIV Franchise, CAR T Therapy Likely to Propel Growth

    Gilead's (GILD) HIV franchise is expected to maintain momentum and offset the decline from the HCV franchise.

  • Gilead's Vemlidy Gets Approval in China for HBV Infection
    Zacks29 days ago

    Gilead's Vemlidy Gets Approval in China for HBV Infection

    Gilead (GILD) obtains approval for Vemlidy in China for the treatment of chronic hepatitis B in adults and adolescents.

  • Better Buy: CRISPR Therapeutics AG vs. Sangamo Therapeutics Inc.
    Motley Foollast month

    Better Buy: CRISPR Therapeutics AG vs. Sangamo Therapeutics Inc.

    This battle goes beyond the merits of CRISPR and zinc-finger nuclease gene-editing approaches.

  • Cutting-edge biotech Sangamo stock dives 12% after JPMorgan cites ‘growing skepticism’ in downgrade
    MarketWatchlast month

    Cutting-edge biotech Sangamo stock dives 12% after JPMorgan cites ‘growing skepticism’ in downgrade

    Sangamo is developing innovative gene-editing programs for many devastating diseases, but a J.P. Morgan analyst called it a ‘show-me story from here.’

  • Sangamo's Shares Drop on Rating Downgrade, Pipeline Woes
    Zackslast month

    Sangamo's Shares Drop on Rating Downgrade, Pipeline Woes

    Sangamo Therapeutics (SGMO) postpones data presentation from its haemophilia study, following dose escalation recommendation from an independent committee. This raises concerns about its development.

  • Here's Why Sangamo Therapeutics Lost 12% Today
    Motley Foollast month

    Here's Why Sangamo Therapeutics Lost 12% Today

    Wall Street is growing increasingly concerned about the progress the company's making with a gene therapy for hemophilia A.

  • MarketWatchlast month

    Sangamo stock drops after J.P. Morgan downgrade

    Sangamo Therapeutics Inc. shares dropped as much as 10% in Wednesday premarket trade before evening out to a 4.6% decline after the company was downgraded to "neutral" at J.P. Morgan, with analyst Eric Joseph citing "growing skepticism about the company's lead development programs and their potential for value creation over the foreseeable future." Joseph also cut the company's price target by nearly 70% to $11. (Company shares closed at $10.80 on Tuesday.) Sangamo is a buzzy biotechnology company that focuses on a type of cutting-edge gene editing that utilizes "zinc finger" proteins. But whether the company's SB-525 program for hemophilia A is working "continues to elude, now with indefinite timelines," Joseph said, questioning whether the company can beat further-along competitors like BioMarin Pharmaceutical Inc. and Spark Therapeutics Inc. . The analyst also had questions about the company's SB-913 program, being developed for a metabolic disorder called Hunter syndrome; early results from a trial were recently released to skepticism, causing Sangamo shares to plummet. "We do believe that the breadth of the pipeline offers several potential catalysts longer term (12-18 months), but with management credibility increasingly coming into play, net-net, we view SGMO as a show-me story from here," Joseph said. Sangamo shares have dropped 32.1% over the last three months, compared with a 3.5% decline in the S&P 500 .

  • A Financial Overview of CRISPR Therapeutics in November
    Market Realistlast month

    A Financial Overview of CRISPR Therapeutics in November

    CRISPR Therapeutics (CRSP) reported revenues of $563,000 in the third quarter—compared to $2.4 million in the third quarter of 2017. CRISPR Therapeutics reported net revenues of $3.0 million over the first nine months of 2018—compared to $8.7 million during the same period in 2017. CRISPR Therapeutics’ net revenues are mainly from collaborations undertaken by the company.

  • CRISPR Therapeutics: Analysts’ View in November
    Market Realistlast month

    CRISPR Therapeutics: Analysts’ View in November

    On November 9, CRISPR Therapeutics’ (CRSP) stock price closed at $36.37, which is an ~3.53% decline from its close of $37.70 on November 8. On November 7, after the company reported its third-quarter financial results, the stock price grew ~10.81% to $38.85 from the close of $35.06 on November 6.

  • Here's Why Sangamo Therapeutics Inc. Fell 25.3% in October
    Motley Foollast month

    Here's Why Sangamo Therapeutics Inc. Fell 25.3% in October

    Following the acquisition of a start-up biotech, Sangamo saw its stock tumble along with the rest of its industry.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of SGMO earnings conference call or presentation 8-Nov-18 10:00pm GMT

    Q3 2018 Sangamo Therapeutics Inc Earnings Call

  • Sangamo Therapeutics (SGMO) Reports Q3 Loss, Lags Revenue Estimates
    Zackslast month

    Sangamo Therapeutics (SGMO) Reports Q3 Loss, Lags Revenue Estimates

    Sangamo (SGMO) delivered earnings and revenue surprises of 0.00% and -41.53%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • PR Newswirelast month

    Sangamo Therapeutics Reports Third Quarter 2018 Financial Results

    RICHMOND, Calif., Nov. 8, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO) today reported third quarter 2018 financial results and recent business highlights. "I'm pleased with our continued execution toward our vision to transform Sangamo into the premier genomic medicines company," said Sandy Macrae, CEO of Sangamo. In September, Sangamo presented 16-week clinical results from the first two cohorts of the Phase 1/2 CHAMPIONS Study evaluating SB-913 for Mucopolysaccharidosis Type II (MPS II), including dose-dependent reductions in glycosaminoglycans (GAGs) in the second cohort (1e13 vector genomes per kilogram of body weight, or vg/kg).

  • PR Newswirelast month

    Sangamo Therapeutics Announces Participation At Upcoming Investor Conferences

    RICHMOND, Calif. , Nov. 6, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that management will participate in the following healthcare investor conferences in November. ...